

INDGN/SE/2026-27/64

29 October 2026

|                                                                                                             |                                                                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BSE Limited,<br>Phiroze Jeejeebhoy Towers,<br>Dalal Street,<br>Mumbai- 400001, India.<br>Scrip Code: 544172 | National Stock Exchange of India Limited<br>Exchange Plaza, C-1, Block G,<br>Bandra Kurla Complex, Bandra (E),<br>Mumbai - 400 051, India.<br>Trading symbol: INDGN |
|-------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Dear Sir / Madam,

**Subject: Press Release regarding financial results for the 2<sup>nd</sup> quarter and half year ended September 30, 2026**  
**Re: Regulation 30 read-with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We wish to inform you that the Company has made a press release dated October 29, 2026, announcing the financial results for the 2<sup>nd</sup> quarter and half year ended September 30, 2026 as approved by the Board of Directors at its meeting held on October 29, 2026. A copy of the Press Release is attached for your records.

This will also be posted on the company's website at: <https://www.indegene.com/>

We request you to kindly take the same on record.

Thanking You

Yours Sincerely,

**For Indegene Limited**

**SRISHTI**  
**RAMESH**  
**KAUSHIK**  
Digitally signed  
by SRISHTI  
RAMESH  
KAUSHIK  
Date: 2026.10.29  
19:53:42 +05'30'

**Srishti Ramesh Kaushik**  
**Company Secretary and Compliance Officer**

Encl: A/a



Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy  
Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru-  
560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777  
compliance.officer@indegene.com  
www.indegene.com

CIN: L73100KA1998PLC102040

Press release

## Indegene Delivers Strong Q2 FY27 Performance, H1 USD Revenue Growth Reaches a Four-Year High

*Q2 INR Revenue Up 39.5% YoY, H1 FY27 USD Revenue Up 27.0% YoY*

**Bengaluru, India, October 29, 2026:** Indegene, the strategic operating partner to the global life sciences industry, announced its financial results for the quarter ended September 30, 2026.

- **Revenue** of ₹11,223M (\$117.5M), up **39.5% YoY (27.5% YoY in \$)** & **5.6% QoQ (4.4% QoQ in \$)**
- **EBITDA** ₹1,873M at **16.7%** margin, up **32.0% YoY**, & **PAT** ₹1,123M at **10.0%** margin, up **10.0% YoY**
- **EBITDA Margin** remained **largely stable** despite **wage hikes**
- Customers generating **\$1M+** annual revenue rose by **5** sequentially to **59**, including **13** in **\$10M+** range
- **Revenue per Employee (RPE)** further strengthened to **\$79.6K** – the highest among peers

| Sl. No. | Particulars                            | Quarter ended |              |              |
|---------|----------------------------------------|---------------|--------------|--------------|
|         |                                        | Sep 30, 2026  | Jun 30, 2026 | Sep 30, 2025 |
| 1.      | Revenue from operations                | 11,223        | 10,631       | 8,042        |
| 2.      | Revenue from operations (\$M)          | 117.5         | 112.5        | 92.2         |
| 3.      | YoY revenue growth from operations (%) | 39.5%         | 39.7%        | 17.1%        |
| 4.      | EBITDA                                 | 1,873         | 1,795        | 1,419        |
| 5.      | EBITDA margin (%)                      | 16.7%         | 16.9%        | 17.6%        |
| 6.      | Profit after tax                       | 1,123         | 1,162        | 1,021        |
| 7.      | Profit margin (%)                      | 10.0%         | 10.9%        | 12.7%        |

“Extending our strong start to FY27, Q2 revenue grew 5.6% sequentially in INR, our fifth successive quarter above 5%. Growth was broad-based, driven by expansion across our top 5 and top 20 accounts and an increase in the number of \$1 million+ clients to 59. We recorded significant deal wins in GenAI-enabled transformation and upstream engagements”, said Manish Gupta, Chairman and CEO, Indegene. “With a healthy pipeline, sustained deal momentum and favourable industry tailwinds, we expect growth and margin expansion to come together in the second half.”

“Despite the annual wage increase that takes effect in our second quarter, EBITDA margin remained stable at 16.7%, a marked improvement on historical Q2 margin trends. Profit after tax grew 10% YoY to INR 1,123 million”, said Suhas Prabhu, CFO, Indegene. “With the wage increase now fully reflected in our cost base, we expect EBITDA to grow faster than revenue in the coming quarters. In addition, higher yields on our investments and lower amortization should help PAT margin expand faster than EBITDA margin.”



## About Indegene

Indegene Limited (BSE: 544172, NSE: INDGN) is the strategic operating partner to the global life sciences industry, orchestrating commercial, medical, R&D, and safety operations across the product lifecycle. Trusted by the world's top 20 biopharma companies, Indegene helps run complex, highly regulated workflows at global scale. Indegene combines deep life sciences expertise with AI-embedded platforms and governed operating models to improve speed, consistency, and compliance across mission-critical operations. By integrating technology into how work is executed and scaled, Indegene enables life sciences organizations to deliver measurable outcomes in regulated environments. For more information, visit [www.indegene.com](http://www.indegene.com)

For investor inquiries, please contact: [IR@indegene.com](mailto:IR@indegene.com)

For media inquiries, please contact: [yadunandan.kv@indegene.com](mailto:yadunandan.kv@indegene.com)